Literature DB >> 18458677

Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment.

S J Bull1, P Huezo-Diaz, E B Binder, J F Cubells, G Ranjith, C Maddock, C Miyazaki, N Alexander, M Hotopf, A J Cleare, S Norris, E Cassidy, K J Aitchison, A H Miller, C M Pariante.   

Abstract

Depression and fatigue are frequent side effects of interferon-alpha (IFN-alpha) treatment, and there is compelling evidence that the inflammatory response system (including interleukin-6, IL-6) and the serotonergic system is important in the pathophysiology of such symptoms. Functional polymorphisms in the promoter region of the IL-6 gene (rs1800795) and serotonin transporter gene (5-HTTLPR) have been identified as regulating these systems. The present study aimed to determine if these polymorphisms were associated with the development of depression and fatigue during IFN-alpha and ribavirin treatment. Ninety-eight Caucasian patients receiving pegylated IFN-alpha and ribavirin treatment for chronic hepatitis C virus at King's College Hospital, London, and Emory University Hospital, Atlanta, participated in this prospective cohort study. Symptoms of depression and fatigue were measured before treatment and at weeks 4, 8, 12 and 24 during treatment. The 'low IL-6' synthesizing genotype (CC) was associated with significantly fewer symptoms of depression (effect size = 0.7 at week 24; F = 9.4, d.f. = 436, P = 0.002). The 'high transcription' serotonin transporter (5-HTT) genotype (LL) was also associated with significantly fewer symptoms of depression, but with a much smaller effect (effect size = 0.2 at week 24; F = 4.5, d.f. = 436, P = 0.03). Neither polymorphisms were associated with symptoms of fatigue (IL-6: F = 1.2, d.f. = 430, P = 0.2; 5-HTT: F = 0.5, d.f. = 430, P = 0.5). The smaller effects of the 5-HTT polymorphism on depression may be explained by an interaction between the genes (F = 5.0, d.f. = 434, P = 0.02): the 'protective' effect of the 5-HTTLPR polymorphism was evident only in the presence of the 'low IL-6' genotype (F = 5.4, d.f. = 64, P = 0.02), not in the presence of the 'high IL-6' genotype (F = 2.2, d.f. = 369, P = 0.1). The association between the IL-6 polymorphism and reduced risk of depressive symptoms confirms the role of the inflammatory response system in the pathophysiology of IFN-alpha-induced depression; in contrast, the effect of the 5-HTT gene was small and perhaps dependent on the status of the inflammatory response.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18458677      PMCID: PMC3513412          DOI: 10.1038/mp.2008.48

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  63 in total

1.  Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state.

Authors:  L Capuron; A Ravaud
Journal:  N Engl J Med       Date:  1999-04-29       Impact factor: 91.245

2.  Psychopathological symptoms during interferon-alpha and ribavirin treatment: effects on virologic response.

Authors:  C Maddock; S Landau; K Barry; P Maulayah; M Hotopf; A J Cleare; S Norris; C M Pariante
Journal:  Mol Psychiatry       Date:  2005-04       Impact factor: 15.992

3.  Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder.

Authors:  Xian-Zhang Hu; Robert H Lipsky; Guanshan Zhu; Longina A Akhtar; Julie Taubman; Benjamin D Greenberg; Ke Xu; Paul D Arnold; Margaret A Richter; James L Kennedy; Dennis L Murphy; David Goldman
Journal:  Am J Hum Genet       Date:  2006-03-28       Impact factor: 11.025

4.  Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction.

Authors:  Charles L Raison; Andrey S Borisov; Sherry D Broadwell; Lucile Capuron; Bobbi J Woolwine; Ira M Jacobson; Charles B Nemeroff; Andrew H Miller
Journal:  J Clin Psychiatry       Date:  2005-01       Impact factor: 4.384

5.  The human serotonin transporter gene linked polymorphism (5-HTTLPR) shows ten novel allelic variants.

Authors:  M Nakamura; S Ueno; A Sano; H Tanabe
Journal:  Mol Psychiatry       Date:  2000-01       Impact factor: 15.992

6.  Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy.

Authors:  Lucile Capuron; Charles L Raison; Dominique L Musselman; David H Lawson; Charles B Nemeroff; Andrew H Miller
Journal:  Am J Psychiatry       Date:  2003-07       Impact factor: 18.112

7.  Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene.

Authors:  Avshalom Caspi; Karen Sugden; Terrie E Moffitt; Alan Taylor; Ian W Craig; HonaLee Harrington; Joseph McClay; Jonathan Mill; Judy Martin; Antony Braithwaite; Richie Poulton
Journal:  Science       Date:  2003-07-18       Impact factor: 47.728

8.  Serotonin transporter genetic variation and the response of the human amygdala.

Authors:  Ahmad R Hariri; Venkata S Mattay; Alessandro Tessitore; Bhaskar Kolachana; Francesco Fera; David Goldman; Michael F Egan; Daniel R Weinberger
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

9.  Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression.

Authors:  M Maes; E Bosmans; R De Jongh; G Kenis; E Vandoolaeghe; H Neels
Journal:  Cytokine       Date:  1997-11       Impact factor: 3.861

10.  The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis.

Authors:  D Fishman; G Faulds; R Jeffery; V Mohamed-Ali; J S Yudkin; S Humphries; P Woo
Journal:  J Clin Invest       Date:  1998-10-01       Impact factor: 14.808

View more
  95 in total

1.  Antagonistic pleiotropy at the human IL6 promoter confers genetic resilience to the pro-inflammatory effects of adverse social conditions in adolescence.

Authors:  Steven W Cole; Jesusa M G Arevalo; Kavya Manu; Eva H Telzer; Lisa Kiang; Julienne E Bower; Michael R Irwin; Andrew J Fuligni
Journal:  Dev Psychol       Date:  2011-07

Review 2.  Sleep disturbance, inflammation and depression risk in cancer survivors.

Authors:  Michael R Irwin; Richard E Olmstead; Patricia A Ganz; Reina Haque
Journal:  Brain Behav Immun       Date:  2012-05-24       Impact factor: 7.217

3.  The serotonin transporter promoter variant (5-HTTLPR), stress, and depression meta-analysis revisited: evidence of genetic moderation.

Authors:  Katja Karg; Margit Burmeister; Kerby Shedden; Srijan Sen
Journal:  Arch Gen Psychiatry       Date:  2011-01-03

Review 4.  Translational approaches to treatment-induced symptoms in cancer patients.

Authors:  Robert Dantzer; Mary W Meagher; Charles S Cleeland
Journal:  Nat Rev Clin Oncol       Date:  2012-05-29       Impact factor: 66.675

Review 5.  Inflammation: depression fans the flames and feasts on the heat.

Authors:  Janice K Kiecolt-Glaser; Heather M Derry; Christopher P Fagundes
Journal:  Am J Psychiatry       Date:  2015-09-11       Impact factor: 18.112

Review 6.  The Immune System and the Role of Inflammation in Perinatal Depression.

Authors:  Philippe Leff-Gelman; Ismael Mancilla-Herrera; Mónica Flores-Ramos; Carlos Cruz-Fuentes; Juan Pablo Reyes-Grajeda; María Del Pilar García-Cuétara; Marielle Danitza Bugnot-Pérez; David Ellioth Pulido-Ascencio
Journal:  Neurosci Bull       Date:  2016-07-18       Impact factor: 5.203

Review 7.  A systematic review of the association between fatigue and genetic polymorphisms.

Authors:  Tengteng Wang; Jie Yin; Andrew H Miller; Canhua Xiao
Journal:  Brain Behav Immun       Date:  2017-01-12       Impact factor: 7.217

8.  Moderators for depressed mood and systemic and transcriptional inflammatory responses: a randomized controlled trial of endotoxin.

Authors:  Michael R Irwin; Steve Cole; Richard Olmstead; Elizabeth C Breen; Joshua Jin Cho; Mona Moieni; Naomi I Eisenberger
Journal:  Neuropsychopharmacology       Date:  2018-11-03       Impact factor: 7.853

9.  Epigenetic changes associated with inflammation in breast cancer patients treated with chemotherapy.

Authors:  Alicia K Smith; Karen N Conneely; Thaddeus W W Pace; Donna Mister; Jennifer C Felger; Varun Kilaru; Mary J Akel; Paula M Vertino; Andrew H Miller; Mylin A Torres
Journal:  Brain Behav Immun       Date:  2014-02-28       Impact factor: 7.217

10.  Cytokine genetic variations and fatigue among patients with breast cancer.

Authors:  Julienne E Bower; Patricia A Ganz; Michael R Irwin; Steven Castellon; Jesusa Arevalo; Steven W Cole
Journal:  J Clin Oncol       Date:  2013-03-25       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.